Clinical trial

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084

StatusACTIVE_NOT_RECRUITING
Study typeINTERVENTIONAL
Start date2021-12-06
PhasePHASE3

Study timeline

Study start (actual)2021-12-06Date precision: day
Registry last updated2026-08-17
Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

What this registered study describes

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial is a interventional study listed under registry identifier NCT05050084. Its last published status is ACTIVE NOT RECRUITING. Registry status does not establish that enrollment is currently open at every study site.

The published record lists 1 condition label(s), 11 intervention label(s), and 2 sponsor/collaborator entry or entries. The structured information below allows these links to be examined individually; intervention registration is not an efficacy claim.

Source: the original ClinicalTrials.gov study record. Always check the protocol, eligibility, dates, results (when posted), and contacts at the original source.

Interventions

BuserelinDRUG · verified · RxNorm: buserelin
DegarelixDRUG · verified · RxNorm: degarelix
FlutamideDRUG · verified · RxNorm: flutamide
GoserelinDRUG · verified · RxNorm: goserelin
HistrelinDRUG · verified · RxNorm: histrelin
LeuprolideDRUG · verified · RxNorm: leuprolide
RelugolixDRUG · verified · RxNorm: relugolix
TriptorelinDRUG · verified · RxNorm: triptorelin

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.